# US 2024/0197737 A1 · Application of compound in preparation of inhibitory drug targeting erbb2 mutant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197737 A1
- Document ID: US20240197737A1
- Status: Published application
- Kind: A1
- Application number: 18/284,162
- Filed: 2022-03-31
- Published: 2024-06-20
- Earliest claimed: 2021-04-01
- Assignees: Shanghai Pharmaceuticals Holding Co., Ltd.
- Applicants: Shanghai Pharmaceuticals Holding Co., Ltd.
- Inventors: Di LI; Lingjun DUAN; Yuan HONG; Zhihui ZHANG; Guangxin XIA; Ying KE
- Web page: https://patentgrep.com/patent/US20240197737A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An application of a compound having a structure represented by chemical formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof, or a crystal form thereof, in particular an application thereof in the preparation of an inhibitory drug targeting an ErbB2 mutant. The provided compound has inhibitory activity against the ErbB2 mutant, and can effectively inhibit proliferation of ErbB2 mutation tumor cells.

## Claims

### Claim 1

A method for inhibiting an ErbB2 mutant in a subject in need thereof, comprising: administering a compound having a structure of chemical formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof, or a crystal form thereof to the subject,
wherein R1 is halogen or C1-C6 alkyl;
R2 is
each R3 is independently
n is 1 or 2;
G is N or C—CN.

### Claim 2 (depends on 1)

The method according to claim 1, wherein in the compound having a structure of chemical formula 1, the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, or the crystal form thereof,
R1 is halogen or C1-C6 alkyl;
R2 is
each R3 is independently
n is 1 or 2;
G is N or C—CN.

### Claim 3 (depends on 1)

The method according to claim 1, wherein in the compound having a structure of chemical formula 1, the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, or the crystal form thereof,
R1 is halogen or C1-C6 alkyl;
R2 is
each R3 is independently
n is 1 or 2;
G is N or C—CN.

### Claim at position 4

4-14. (canceled)

### Claim 15 (depends on 1)

The method according to claim 1, wherein in the chemical formula 1, when R1 is halogen, the halogen is Cl; when R1 is C1-C6 alkyl, the C1-C6 alkyl is methyl;
or,
when n is 1, R3 is
when n is 2, R3 is two neighboring groups, one of which is
and the other group is
or, R2 is

### Claim 16 (depends on 15)

The method according to claim 15, wherein when n is 1, R3 is
when n is 2, R3 is two neighboring groups, one of which is
and the other group is

### Claim 17 (depends on 16)

The method according to claim 16, wherein the compound having a structure of chemical formula 1 is one or more compounds selected from (R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrol-2-yl)acrylamide, Lapatinib, Tucatinib, Pyrotinib, Neratinib,

### Claim 18 (depends on 1)

The method according to claim 1, wherein the ErbB2 mutant has a mutation type including one or more of D769H, D769Y, R896C, V777L, G766>VC, and A775_G776insYVMA.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the ErbB2 mutation type is D769H, D769Y, R896C, V777L, G766>VC, or A775_G776insYVMA, and the compound having a structure of chemical formula 1 is (R,Z)-N-(4-44-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrol-2-yl)acrylamide;
or, the ErbB2 mutation type is D769H, D769Y, R896C, V777L, or A775_G776insYVMA, and the compound having a structure of chemical formula 1 is Lapatinib;
or, the ErbB2 mutation type is D769H, D769Y, R896C, or V777L, and the compound having a structure of chemical formula 1 is Tucatinib;
or, the ErbB2 mutation type is D769H, D769Y, R896C, or V777L, and the compound having a structure of chemical formula 1 is Pyrotinib;
or, the ErbB2 mutation type is D769H, D769Y, R896C, or V777L, and the compound having a structure of chemical formula 1 is Neratinib;
or, the ErbB2 mutation type is D769H, D769Y, R896C, or V777L, and the compound having a structure of chemical formula 1 is any one of the following structures:

### Claim 20 (depends on 1)

The method according to claim 1, wherein the compound having a structure of chemical formula 1 is the sole active ingredient, or act as an active ingredient in conjunction with other ErbB2 mutant inhibitors or medicaments for the treatment of cancer.

### Claim 21 (depends on 1)

The method according to claim 1, wherein the content of the compound having a structure of chemical formula 1 is the content that achieves a therapeutically effective amount.

### Claim 22

A method for the treatment or prevention of a disease related to a ErbB2 mutant in a subject in need thereof, comprising: administering a compound having a structure of chemical formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof, or a crystal form thereof to the subject;
wherein R1 is halogen or C1-C6 alkyl;
R2 is
each R3 is independently
n is 1 or 2;
G is N or C—CN.

### Claim 23 (depends on 22)

The method according to claim 22, wherein in the compound having a structure of chemical formula 1, the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, or the crystal form thereof,
wherein R1 is halogen or C1-C6 alkyl;
R2 is
each R3 is independently
n is 1 or 2;
G is N or C—CN.

### Claim 24 (depends on 22)

The method according to claim 22, wherein in the compound having a structure of chemical formula 1, the pharmaceutically acceptable salt thereof, the solvate thereof, the solvate of the pharmaceutically acceptable salt thereof, or the crystal form thereof,
R1 is halogen or C1-C6 alkyl;
R2 is
each R3 is independently
n is 1 or 2;
G is N or C—CN.

### Claim 25 (depends on 22)

The method according to claim 22, wherein in the chemical formula 1, when R1 is halogen, the halogen is Cl; when R1 is C1-C6 alkyl, the C1-C6 alkyl is methyl;
or,
when n is 1, R3 is
preferably
when n is 2, R3 is two neighboring groups, one of which is
and the other group is
preferably
or, R2 is
preferably, the compound having a structure of chemical formula 1 is one or more compounds selected from (R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrol-2-yl)acrylamide, Lapatinib, Tucatinib, Pyrotinib, Neratinib,

### Claim 26 (depends on 22)

The method according to claim 22, wherein the ErbB2 mutant has a mutation type including one or more of D769H, D769Y, R896C, V777L, G766>VC, and A775_G776insYVMA.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the ErbB2 mutation type is D769H, D769Y, R896C, V777L, G766>VC, or A775_G776insYVMA, and the compound having a structure of chemical formula 1 is (R,Z)-N-(4-((4-([1,2,4]triazolo [1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrol-2-yl)acrylamide;
or, the ErbB2 mutation type is D769H, D769Y, R896C, V777L, or A775_G776insYVMA, and the compound having a structure of chemical formula 1 is Lapatinib;
or, the ErbB2 mutation type is D769H, D769Y, R896C, or V777L, and the compound having a structure of chemical formula 1 is Tucatinib;
or, the ErbB2 mutation type is D769H, D769Y, R896C, or V777L, and the compound having a structure of chemical formula 1 is Pyrotinib;
or, the ErbB2 mutation type is D769H, D769Y, R896C, or V777L, and the compound having a structure of chemical formula 1 is Neratinib;
or, the ErbB2 mutation type is D769H, D769Y, R896C, or V777L, and the compound having a structure of chemical formula 1 is any one of the following structures:

### Claim 28 (depends on 22)

The method according to claim 22, wherein the disease related to the ErbB2 mutant is ErbB2 mutant cancer;
the ErbB2 mutant cancer preferably comprises breast cancer, colon cancer, head and neck cancer, bladder cancer, gastric cancer, ovarian cancer, liver cancer, or lung cancer;
the lung cancer is further preferably non-small cell lung cancer.

### Claim 29 (depends on 22)

The method according to claim 22, wherein the treatment is inhibition of tumor metastasis and/or growth.

### Claim 30 (depends on 22)

The method according to claim 22, wherein the compound having a structure of chemical formula 1 is the sole active ingredient, or act as an active ingredient in conjunction with other ErbB2 mutant inhibitors or medicaments for the treatment of cancer.

### Claim 31 (depends on 22)

The method according to claim 22, wherein the content of the compound having a structure of chemical formula 1 is the content that achieves a therapeutically effective amount.
